VRTX - VERTEX PHARMACEUTICALS INC / MA
IEX Last Trade
402.38
1.765 0.439%
Share volume: 14,772
Last Updated: Tue 31 Dec 2024 08:30:19 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.09%
PREVIOUS CLOSE
CHG
CHG%
$400.62
1.77
0.44%
View ratios
| Fiscal Date | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2023-05-02 | 2023-08-02 | 2023-11-07 | 2024-02-15 | 2024-05-07 | 2024-08-02 | |
| Total revenue | 2.375 B | 2.493 B | 2.484 B | 2.518 B | 2.691 B | 2.646 B | |
| Cost of revenue | 266.900 M | 308.600 M | 318.700 M | 368.000 M | 342.600 M | 371.900 M | |
| Gross profit | 2.108 B | 2.185 B | 2.165 B | 2.150 B | 2.348 B | 2.274 B | |
| 3.64% | -0.91% | -0.70% | 9.22% | -3.16% | |||
| Operating expenses | 983.700 M | 1.048 B | 1.074 B | 1.194 B | 1.132 B | 1.339 B | |
| Selling general and admin | 241.100 M | 262.600 M | 263.800 M | 369.100 M | 342.700 M | 372.200 M | |
| Research and development | 742.600 M | 785.700 M | 810.000 M | 824.600 M | 789.100 M | 966.600 M | |
| Total expenses | 1.251 B | 1.357 B | 1.393 B | 1.562 B | 1.474 B | 1.711 B | |
| 8.50% | 2.62% | 12.15% | -5.59% | 16.03% | |||
| Operating income | 1.124 B | 1.136 B | 1.091 B | 956.000 M | 1.216 B | 934.900 M | |
| Ebit | 1.124 B | 1.136 B | 1.091 B | 956.000 M | 1.216 B | 934.900 M | |
| Pretax income | 891.500 M | 1.162 B | 1.179 B | 1.148 B | 1.279 B | -3.391 B | |
| 30.29% | 1.52% | -2.68% | 11.46% | -365.12% | |||
| Income tax | 191.700 M | 245.800 M | 143.900 M | 178.800 M | 179.500 M | 202.400 M | |
| Net income basic | 699.800 M | 915.700 M | 1.035 B | 968.800 M | 1.100 B | -3.594 B | |
| 30.85% | 13.06% | -6.42% | 13.50% | -426.81% | |||
| Net income | 699.800 M | 915.700 M | 1.035 B | 968.800 M | 1.100 B | -3.594 B | |
| 30.85% | 13.06% | -6.42% | 13.50% | -426.81% |